MLMinghe Lv

Minghe Lv

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Minghe Lv has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Jingping Yu

    Department of Radiotherapy, Changzhou Cancer Hospital, Changzhou, China

    3 shared publications
  • Juefeng Wan

    Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

    2 shared publications
  • Ruping Zhao

    Department of Radiotherapy, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications
  • Shali Shao

    Center for Tumor Diagnosis and Therapy Jinshan Hospital Fudan University Jinshan District Shanghai 201508 China fudan.edu.cn

    2 shared publications
  • Su Zeng

    Department of Radiotherapy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications
  • Tiankui Qiao

    Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China

    2 shared publications

Latest Publications

    • 1 March 2026
      • Vol. 27  (3) , e70524
    Open Access

    Accumulated dose on daily iCBCT for rectal cancer: Effects of inter-fraction bowel cavity motion volume.

    by Hongwei Zeng, Xiangyu E, Su Zeng, Yue Feng, Jingping Yu, Minghe Lv, Ruping Zhao

    To assess how inter-fraction bowel cavity (BC) motion volume influences accumulated dose in rectal cancer radiotherapy and to translate these effects into a clinically interpretable risk construct for acute bowel toxicity. This retrospective cohort included 28 consecutive rectal cancer patients treated with 50 Gy in 25 fractions on a Halcyon v3.0 linac with daily iterative cone beam CT (iCBCT). Patients with > 5% bladder-volume or > 8% external-contour variation across the course were excluded. For each fraction, per-fraction dose was recalculated on the iCBCT using a scanner-specific HU-relative electron density calibration, rigidly aligned to the planning CT (pCT), deformably registered, and voxel-wise accumulated on pCT. Dosimetric endpoints were PTV D2%, D50%, D98% and whole-bowel (WB) D0.03cc, D150cc. Associations between inter-fraction BC motion volume change (ΔVBC) and accumulated dose difference (ΔD) were quantified using Spearman's f and ordinary-least-squares slopes (Gy per 10% BC expansion); same-day effects were estimated with patient fixed-effects models. To account for multiple testing, p-values for the five primary endpoints were adjusted using the Benjamini-Hochberg false discovery rate (FDR). Clinical relevance was assessed with a published logistic normal-tissue complication probability (NTCP) model based on WB V45, defined as the WB volume receiving ≥ 45 Gy. Accumulated dose analyses showed selective elevation of high-dose metrics with preservation of near-minimum target coverage. Compared with the plan, accumulated PTV D2% and D50% increased by 0.87 Gy and 0.61 Gy, respectively, whereas PTV D98% exhibited no meaningful change. WB D0.03cc and D150cc increased by 1.21 Gy and 1.18 Gy, respectively. Inter-fraction BC expansion was strongly associated with high-dose escalation: for each 10% increase in BC volume, accumulated WB D0.03cc increased by 0.31 Gy (95% CI 0.18-0.44; ρ = 0.78) and PTV D2% by 0.29 Gy (0.15-0.37; ρ = 0.66). After FDR adjustment, no endpoint met p < 0.05, but the strongest associations (PTV D2%, WB D0.03cc) remained near-significant and directionally consistent with large, biologically plausible effect sizes. Application of the WB V45 NTCP model indicated modest but consistent risk increments after accumulation, with NTCP for ≥ grade 2 toxicity increasing from 0.75 to 0.79 (+0.04; p = 0.001) and NTCP for grade 3 toxicity increasing from 0.80 to 0.84 (+0.04; p = 0.002). Daily iCBCT-based dose accumulation identifies inter-fraction BC motion volume as a selective driver of high-dose escalation to the PTV and WB while largely preserving near-minimum target coverage. Accumulated WB V45 may serve as a practical, delivery-based marker for on-treatment surveillance and risk-adapted intervention, complementing plan-based evaluation in rectal cancer radiotherapy.

  • Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma

    by Minghe Lv, Lei Tang, Liu Yang, Jingping Yu, Qing Ji, Ruping Zhao

    Background Cisplatin (CDDP) resistance represents an urgent clinical challenge. Identifying CDDP-resistant lung adenocarcinoma (LUAD) patients responsive to immunotherapy through novel biomarkers is critical for improving survival outcomes. Methods CDDP resistance genes were identified from RNA-seq data of A549 cells in the GEO database. RNA sequencing, genetic mutations, and clinical data of LUAD patients were obtained from TCGA. Patients were split into training and validation cohorts. A prognostic model was developed using LASSO and multivariate Cox regression, with validation in both cohorts. Tumor mutation burden (TMB), immune activity, and functional enrichment analyses (GO, KEGG) were performed to explore the link between lncRNA and CDDP resistance. Results Twenty-three CDDP resistance-associated genes were identified from GEO. Co-expression analysis revealed 507 CDDP resistance-linked lncRNAs. Cox regression analysis identified three CDDP resistance-related lncRNAs: ARAP1-AS2, LINC01843, and LINC02198. RT-PCR verified these lncRNAs and representative mRNAs (KIF21B, B3GNT3, PLXNA2). Patients stratified by median risk score showed significantly worse overall survival (OS) and higher mortality in high-risk groups. Univariate/multivariate Cox analyses confirmed the risk score as an independent prognostic factor. A nomogram predicted LUAD survival outcomes. Low-risk patients exhibited significantly lower TMB than high-risk counterparts, with low-risk/high-TMB patients showing optimal OS. The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm revealed significant differences in immune dysfunction, CD8+ T cells, cancer-associated fibroblasts (CAF), and tumor-associated macrophages (TAM-M2) between risk groups. Conclusion These three CDDP resistance-associated lncRNAs including ARAP1-AS2, LINC01843, and LINC02198, serve as reliable prognostic biomarkers for LUAD. The findings provide insights for immunotherapeutic strategies and personalized treatment development.


  • Open Access

    The predictive value of LGR for distant metastasis-free survival in locally advanced rectal cancer patients

    by Minghe Lv, Songsong Wu, Zhiyuan Zhang, Zhen Zhang, Juefeng Wan


  • Network Pharmacology Analysis on the Mechanism of Xihuangwan in Treating Rectal Cancer and Radiation Enteritis

    by Minghe Lv, Rong Ding, Peizhen Ma, Yue Feng, Su Zeng, Yang Zhang, Wenhao Shen, Wenhui Guan, Xiangyu E., Hongwei Zeng, et al.

    Background: Recent studies have shown that XihuangWan (XHW) is a kind of Chinese medicine with significant anti-tumor and anti-inflammatory activities. However, its mechanism for preventing and treating radiation proctitis in rectal cancer patients during radiotherapy remains unclear. Methods: This study employed the network pharmacology to establish a “drug-active ingredient-target genedisease” network via using TCMSP, SymMap, GeneCard, and OMIM databases. The PPI network was conducted by the String tool. The core targets of XHW in the treatment of rectal cancer and radiation enteritis were identified by topological analysis, and the functional annotation analysis and pathway enrichment analysis were performed. Results: A total of 61 active ingredients of XHW ingredients, 4607 rectal cancer-related genes, 5803 radiation enteritis-related genes, and 68 common targets of XHW in the treatment of rectal cancer and radiation enteritis were obtained. PTGS1 and NR3C2, as identified potential targets, were significantly associated with OS of colorectal cancer patients. GO and KEGG enrichment analysis showed that bioinformatics annotation of these common genes was mainly involved in DNA-binding transcription factor, PI3K/Akt, TNF, HIF-1 signaling pathway, and colorectal cancer pathway. Conclusion: The active ingredients of XHW, mainly including Quercetin, Ellagic acid, and Stigmasterol, might act on common targets of rectal cancer and radiation enteritis, such as PTGS1, NR3C2, IL-6, EGFR, HIF-1A, CASP3, BCL2, ESR1, MYC, and PPARG, and regulate multiple signaling pathways like PI3K-Akt, TNF, and HIF-1 to inhibit tumor proliferation, tumor angiogenesis, inflammatory responses, and oxidative stress, thereby achieving prevention and treatment of radiation enteritis in rectal cancer patients during radiotherapy. It provided an important reference for further elucidating the anti-inflammation and anti-tumor mechanism and clinical application of XHW.


  • Open Access

    Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients

    by Minghe Lv, Shali Shao, Yajing Du, Xibing Zhuang, Xiangdong Wang, Tiankui Qiao

    Background. Advanced lung cancer that contributes to a heavy burden on medical institutions is the leading cause of cancer-related death and is often accompanied by metabolic disorders. In this study, we aimed to explore the biomarkers of diagnosis and radiotherapy response in non-small-cell lung cancer (NSCLC) patients by plasma lipidomics analysis. Method. Using triple-quadrupole mass spectrometer analysis, our research characterized the plasma lipid metabolomics profile of 25 healthy controls and 31 advanced NSCLC patients in each of three different radiotherapy phases. Results. The results showed altered lipid elements and concentrations among NSCLC patients with different radiotherapy phases, NSCLC subtypes, and different radiotherapeutic responses. We found that compared to the healthy controls, myelin-associated glycoprotein (MAG), phosphatidylinositol (PI), and phosphatidylserine (PS) were mainly and significantly altered lipid elements (> twofold, and ) among NSCLC patients with different radiotherapy phases. Through comparison of lipid elements between bad and good responses of NSCLC patients with radiotherapy, the obviously declined phosphatidylglycerol (PG 18 : 0/14 : 0, 18 : 1/18 : 3, and 18 : 0/20 : 1) or markedly elevated PI (20 : 0/22 : 5 and 18 : 2/22 : 4) and phosphatidic acid (PA 14 : 0/20 : 4, 14 : 0/20 : 3, and 18 : 2/22 : 4) could indicate poor therapeutic response for NSCLC patients. The results of ROC curve analysis suggested that PG (18 : 0/20 : 1 and 18 : 0/14 : 0) could clearly predict the radiotherapeutic response for NSCLC patients, and PS (18 : 0/20 : 0) and cholesterol were the first two lipid components with the most potential for the diagnosis of advanced NSCLC. Conclusion. Our results indicated that plasma lipidomics profiling might have a vital value to uncover the heterogeneity of lipid metabolism in healthy people and advanced NSCLC patients with different radiotherapy phase, and further to screen out radiotherapeutic response-specific biomarkers.


  • Open Access

    The predictive value of lymphocyte to monocyte ratio for overall survival in cholangiocarcinoma patients with hepatic resection

    by Minghe Lv, Kun Wang, Zhiyuan Zhang, Zhen Zhang, Juefeng Wan

    Background: There is considerable heterogeneity in clinical behavior and survival outcomes in patients with cholangiocarcinoma (CCA), and the prognosis of CCA patients is poor. We proposed lymphocyte to monocyte ratio (LMR) as a novel prognostic element for CCA patients with hepatic resection in present study.Methods: By retrospectively analyzing the clinical data of 145 CCA patients with hepatic resection, we determined the optimal LMR cutoff value according to the receiver operating characteristic (ROC). We comparatively analyzed the clinical features of CAA patients between low LMR group and high LMR group, mainly including overall survival (OS) analysis by using the Kaplan‐Meier method, univariate and multivariate Cox regression.Results: We found there was a longer OS in CCA patients of the high LMR group than the low LMR group. The total median OS of cholangiocarcinoma patients were 13.6 months, and the OS of low LMR group was markedly lower than the high LMR group. The 1‐year, 3‐year, and 5‐year OS of high LMR group were respectively 62.9%, 32.4%, and 16.4%, and were significantly higher the cholangiocarcinoma patients of low LMR group (40.2%, 16.4%, and 0%). Multivariate regression analyses showed that preoperative cholangitis, elevated CEA level and nerve invasion were risk factors for the OS of cholangiocarcinoma patients, while the high LMR level and postoperative treatment were protective factors for the OS of cholangiocarcinoma patients.Conclusions: Preoperative LMR was a vital prognostic factor to predict the prognosis of CCA patients with hepatic resection and provided additional prognostic value beyond standard clinicopathological parameters.


  • Open Access

    MYL5 as a Novel Prognostic Marker is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study

    by Minghe Lv

    Background. Myosin light chain plays a vital regulatory function in a large-scale cellular physiological procedure, however, the role of myosin light chain 5 (MYL5) in breast cancer has not been reported. In this study, we aimed to elucidate the effects of MYL5 on clinical prognosis and immune cell infiltration, and further explore the potential mechanism in breast cancer patients. Methods. In this study, we first explored the expression pattern and prognostic value of MYL5 in breast cancer across multiple databases, including Oncomine, TCGA, GTEx, GEPIA2, PrognoScan, and KaplanMeier Plotter. The correlations of MYL5 expression with immune cell infiltration and associational gene markers in breast cancer were analyzed by using the TIMER, TIMER2.0, and TISIDB databases. The enrichment and prognosis analysis of MYL5-related genes were implemented by using LinkOmics datasets. Results. We found that there was a low expression of MYL5 in breast cancer than in corresponding normal tissue by analyzing the data from Oncomine and TCGA datasets. Furthermore, research showed the prognosis of the MYL5 high-expression group was better than the low-expression group in breast cancer patients. Furthermore, MYL5 expression is markedly related to the tumor-infiltrating immune cells (TIICs), including cancer-associated fibroblast, B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil, and dendritic cell, and related to immune molecules as well as the associated gene markers of TIICs. Conclusion. MYL5 can serve as a prognostic signature in breast cancer and is associated with immune infiltration. This study first offers a relatively comprehensive understanding of the oncogenic roles of MYL5 for breast cancer.


  • Open Access

    WD repeat domain 6 as a novelty prognostic biomarker correlates with immune infiltration in lung cancer: A preliminary study

    by Minghe Lv

    Background: WD repeat domain 6 (WDR6), a novel human WD‐repeat gene, encodes a member of the WD repeat protein family, and its tumorigenic effect has rarely been reported so far.Methods: Our study used Oncomine, TIMER2.0, GEPIA2, Kaplan–Meier plotter, PrognoScan, and TISIDB tools to analyze the differential expression between pan‐cancer, especially lung cancer, and corresponding normal tissue, and further explore the prognostic and immunological role of WDR6 expression.Results: Our results showed WDR6 was lower expressed in lung squamous cell carcinoma than in normal tissue, but WDR6 expression was correlated obviously with clinical stage in Lung adenocarcinoma. The overall survival, first progression, postprogression survival, and Relapse‐free survival of lung cancer patients were longer in the WDR6 high‐expression group than in the low‐expression group. We found the expression of WDR6 significantly correlated with immune molecules, including immunomodulators, lymphocytes, and chemokines in lung cancer.Conclusion: WDR6 can be used as a prognostic marker for lung cancer and is significantly associated with immune cell infiltration.


  • Open Access

    Myeloid-Derived Suppressor Cells and CD68+CD163+M2-Like Macrophages as Therapeutic Response Biomarkers Are Associated with Plasma Inflammatory Cytokines: A Preliminary Study for Non-Small Cell Lung Cancer Patients in Radiotherapy

    by Minghe Lv, Xibing Zhuang, Shali Shao, Xuan Li, Yunfeng Cheng, Duojiao Wu, Xiangdong Wang, Tiankui Qiao

    Background. Recent studies show that myeloid-derived suppressor cells (MDSCs) and M2-like macrophages are involved in the treatment of tumors; however, their therapeutic response role is rarely known in non-small cell lung cancer (NSCLC) during radiotherapy. We aim to explore the dynamic alteration of the circulating MDSCs and M2-like macrophages, to examine their relationship, and to evaluate their therapeutic response value for NSCLC patients in radiotherapy. Methods. Peripheral blood mononuclear cells from healthy controls and NSCLC patients with different radiotherapy phases were isolated to examine the circulating MDSCs and M2-like macrophages by flow cytometry. 40 plasma inflammatory cytokines were measured by multiplex ELISA. Results. In comparison with healthy controls, the percentages of MDSCs and CD68+CD163+M2-like macrophages of NSCLC patients were significantly elevated and were distinctly higher in radiotherapy than in preradiotherapy. MDSCs were correlated positively with CD68+CD163+M2-like macrophages in NSCLC patients in radiotherapy and postradiotherapy. Especially, we found that in comparison with those in the poor group, the percentages of two cells in the good response group were markedly increased during radiotherapy and they had a significantly positive correlation. During radiotherapy, the proportions of MDSCs were clearly increased in adenocarcinoma patients and the percentages of CD68+CD163+M2-like macrophages were markedly elevated in squamous carcinoma patients. We found that after radiotherapy, the expressions of eotaxin, MIP-1β, MCP-1, and BLC were significantly increased in NSCLC patients. Further results showed that the low levels of eotaxin and TNF RII expression before radiotherapy could predict a good therapeutic response. IL-1ra and MIP-1β had a positive relation with MDSCs or CD68+CD163+M2-like macrophages in NSCLC patients during radiotherapy, and eotaxin was correlated with CD68+CD163+M2-like macrophages but not MDSCs in NSCLC patients after radiotherapy. Conclusions. MDSCs and CD68+CD163+M2-like macrophages serve as therapeutic response biomarkers and are associated with the expressions of plasma inflammatory cytokines for NSCLC patients during radiotherapy.


  • Open Access

    The landscape of prognostic and immunological role of myosin light chain 9 (MYL9) in human tumors

    by Minghe Lv, Lumeng Luo, Xue Chen

    Introduction: Recent studies have shown that myosin light chain 9 (MYL9) plays a vital role in immune infiltration, tumor invasion, and metastasis; however, the prognostic and immunological role of MYL9 has not been reported. The purpose of this study was to explore the potential prognostic and immunological roles of MYL9 in human cancers by public datasets mainly including the cancer genome atlas (TCGA) and Gene expression omnibus.Methods: The expression pattern and prognostic value of MYL9 were analyzed across multiple public datasets in different cancer. The correlations between MYL9 expression and immune infiltration among multiple cancers were analyzed by using the TIMER2.0. The MYL9‐related gene enrichment analysis was implemented by mainly using KEGG and GO datasets.Results: MYL9 was lowly expressed in most cancers, such as breast cancer, lung adenocarcinoma and squamous cell carcinoma, and stomach adenocarcinoma; but it was highly expressed in several cancers, such as cholangiocarcinoma, head and neck squamous cell carcinoma, and liver hepatocellular carcinoma. Furthermore, MYL9 expression was distinctively associated with prognosis in adrenocortical carcinoma, colon adenocarcinoma, brain glioma, lung cancer, ovarian cancer, gastric cancer, breast cancer, blood cancer, and prostate cancer patients. The expressions of MYL9 were significantly associated with the infiltration of cancer‐associated fibroblasts, B cell, CD8+T cell, CD4+T cell, macrophage, neutrophil, dendritic cell in different tumors as well as immune markers. In addition, we found that the functional mechanisms of MYL9 involved muscle contraction and focal adhesion.Conclusion: MYL9 can serve as a prognostic signature in pan‐cancer and is associated with immune infiltration. This pan‐cancer study is the first to show a relatively comprehensive understanding of the prognostic and immunological roles of MYL9 across different cancers.